Pyxis Oncology Stock Quote PYXS - Stock Price, News, Charts, Message Board, Trades

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Pyxis Oncology Inc (PYXS) Quote

Pyxis Oncology Inc (PYXS)

4.31

-0.07

(-1.60%)

Closed May 06 4:00PM

Delayed by 15 minutes

4.31

0.00

( 0.00% )

Pre Market: 7:01AM

Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Current Price

4.31

Bid

4.25

Ask

4.44

Volume

2

0.00 Day's Range 0.00

1.35 52 Week Range 6.85

Market Cap

Previous Close

4.31

Open

-

Last Trade

Last Trade Time

04:43:11

Financial Volume

-

VWAP

-

Average Volume (3m)

756,519

Shares Outstanding

44,323,046

Dividend Yield

-

PE Ratio

-2.59

Earnings Per Share (EPS)

-1.66

Revenue

-

Net Profit

-73.79M

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the ... Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

pyxisoncology.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Pyxis Oncology Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PYXS. The last closing price for Pyxis Oncology was $4.31. Over the last year, Pyxis Oncology shares have traded in a share price range of $ 1.35 to $ 6.85.

Pyxis Oncology currently has 44,323,046 shares outstanding. The market capitalization of Pyxis Oncology is $191.03 million. Pyxis Oncology has a price to earnings ratio (PE ratio) of -2.59.

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by...

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement...

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The PYX-201 target EDB+FN is found overexpressed...

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.09	-2.04545454545	4.4	4.78	4.24	424997	4.38124899	CS
4	-1.22	-22.061482821	5.53	5.68	4.06	438921	4.61883253	CS
12	-0.42	-8.87949260042	4.73	6.85	3.6	756519	5.21788636	CS
26	2.59	150.581395349	1.72	6.85	1.35	580479	4.43326477	CS
52	1.46	51.2280701754	2.85	6.85	1.35	417029	3.9164525	CS
156	-14.69	-77.3157894737	19	19	1.1	602553	4.25079097	CS
260	-14.69	-77.3157894737	19	19	1.1	602553	4.25079097	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AIREreAlpha Tech Corporation	$ 1.38 (61.12%)	3.36M
ESPREsperion Therapeutics Inc	$ 2.72 (28.30%)	3.6M
DYNTDynatronics Corp	$ 0.58 (25.11%)	79
GTBPGT Biopharma Inc	$ 4.00 (24.22%)	45
JUNEJunee Ltd	$ 5.88 (24.05%)	22
GPGreenPower Motor Company Inc	$ 1.20 (-34.07%)	53.54k
AGRIAgriFORCE Growing Systems Ltd	$ 0.0983 (-31.93%)	415.55k
HSDTHelius Medical Technologies Inc	$ 2.05 (-15.29%)	68.36k
NUVOHoldco Nuvo Group DG Ltd	$ 4.45 (-15.24%)	62.74k
LYRALyra Therapeutics Inc	$ 0.4523 (-13.27%)	1.59M
FFIEFaraday Future Intelligent Electric Inc	$ 0.0459 (11.14%)	13.17M
ESPREsperion Therapeutics Inc	$ 2.72 (28.30%)	3.6M
AIREreAlpha Tech Corporation	$ 1.38 (61.12%)	3.36M
FGENFibroGen Inc	$ 1.38 (18.97%)	3.31M
TCBPTC BioPharm Holdings PLC	$ 1.57 (8.28%)	1.87M

Monksdream

Monksdream 1 month ago

Awl416

Awl416 2 months ago

Pyxis Oncology Announces $50 Million Private Placement

euroconversions

euroconversions 8 months ago

Insiders buying, always a good sign.
PYXS Long

jack7377

jack7377 12 months ago

PYSX#$$: Hey Bulba and JuneBugs , this Log Legged Loin Puppy is getting ready to Break it's Chain,Leap and go on an Epic Run North. Friday's 1st Qtr Financials are going to make this spring 200-300%.

TheFinalCD

TheFinalCD 1 year ago

I did, nice P&D

https://www.tiktok.com/@stockdads/video/7217125391520091434

SpaceTimeRift777

SpaceTimeRift777 1 year ago

Wouldn't touch it until we see if that $3 support can hold
GL

spencer22

spencer22 1 year ago

Perfect example of dilution,in other words a classic pump and dump in my opinion!

0210

0210 1 year ago

7). $10.75 PYXS Target Price @ Fin Viz.

8). BUY Rating $14.00 PYXS PT @ Market Beat.

9). $10.75 PT +++Positive+++ Short, Medium and Long Term Performance Outlook, Yahoo Finance.

10). BUY Rating @Reuters.

0210

0210 1 year ago

buyin' dips $4.00 - $4.10. 14m BUYs (+5m?) vs. 12m Sells this Friday. hmmm.....

1). 88% Buy, up from 72% buy last week and 40% Buy, a month ago @Barchart.

2). Stay Long @ American Bulls.

3). $10.75 Price Target, from 5 analysts @Barrons.

4). $4.00 >$11.50 > $16.00 Price Targets @CNN Business.

5). HOLD Rating @ Zacks.

6). $11.22 TP mean rating, Chartmill.

interloper

interloper 1 year ago

I just heard the same thing from a cousin who said it was on Reddit.

Jess070283

Jess070283 1 year ago

That dip was a gift. Loaded way oversold.

magacrew2020

magacrew2020 1 year ago

potential halt at $2. seems to be fair value

da_stock_analyst

da_stock_analyst 1 year ago

#PYXS ?? big squeeze coming??!! Attractive bullish chart! $PYXS

Pyramid2

Pyramid2 1 year ago

* * > $7 halt < * *

Went short $6.85 and they halted it $6.92 and she dropped. I thought not again just like SVIBQ and it will open 2 weeks later at $100. I am still waiting to get my trading groove back. This thing has been a rocket from $3.92 yesterday. No position now closed out on $6 close.

glta.

SpaceTimeRift777

SpaceTimeRift777 1 year ago

Better lock profits today this will come back down to earth

Way Overbought

SpaceTimeRift777

SpaceTimeRift777 1 year ago

One hell of a Moon Market pump

jakec21

jakec21 1 year ago

Please post something that you have proof. You r on my radar alert

TrendTrade2016

TrendTrade2016 1 year ago

PYXS....MONSTER TAKING OFF!!

PickItToWin

PickItToWin 1 year ago

Thorough DD is how I found my info and jumped in at $2. Definitely happy with my ROI this week, hope others took advantaged as well. GLTA

eastunder

eastunder 1 year ago

It's from a tiktok video...

Where all valid information comes from.

da_stock_analyst

da_stock_analyst 1 year ago

#PYXS ?? can it double from here? very bullish chart! see the video $PYXS

TheFinalCD

TheFinalCD 1 year ago

hmmmm, any info or articles to back your post up?

Message in reply to:
Target price is $12-$16. Nancy Pelosi’s husband just scooped up a bunch of PYXS and he somehow always has the inside scoop on stocks ;)

Jess070283

Jess070283 1 year ago

Randyfloyd420

Randyfloyd420 1 year ago

Yea what a joke

eastunder

eastunder 1 year ago

I did. There is nothing that I found that backed that up.

So if you have something, cam you please post a link?

I really am curious.

I don't see Pelosi buying something like this.

Why?

PickItToWin

PickItToWin 1 year ago

Just do a Google search on Pyxs and Nancy Pelosi. She’s not the only one buying it up.

eastunder

eastunder 1 year ago

How do you know that?

PickItToWin

PickItToWin 1 year ago

Target price is $12-$16. Nancy Pelosi’s husband just scooped up a bunch of PYXS and he somehow always has the inside scoop on stocks ;)

Amatuer17

Amatuer17 1 year ago

Seems an interesting play in ADC

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions